The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.

Autor:	Smith AM; Siemens Medical Solutions USA, Inc., Knoxville, Tennessee; anne.m.smith@siemens-healthineers.com., Obuchowski NA; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio., Foster NL; Department of Neurology, University of Utah, Salt Lake City, Utah., Klein G; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Mozley PD; Weill Medical College of Cornell University, New York, New York., Lammertsma AA; Amsterdam Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.; Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Wahl RL; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.; Department of Radiation Oncology, Washington University in Saint Louis, St. Louis, Missouri., Sunderland JJ; Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, Iowa., Vanderheyden JL; JLVMI Consulting LLC, Dousman, Wisconsin., Benzinger TLS; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.; Department of Radiation Oncology, Washington University in Saint Louis, St. Louis, Missouri., Kinahan PE; Department of Radiology, School of Medicine, University of Washington, Seattle, Washington., Wong DF; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri., Perlman ES; Perlman Advisory Group, Hillsdale, New York., Minoshima S; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah; and., Matthews D; ADM Diagnostics, Inc., Northbrook, Illinois.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Feb; Vol. 64 (2), pp. 294-303. Date of Electronic Publication: 2022 Sep 22.
DOI:	10.2967/jnumed.122.264031
Abstrakt:	A standardized approach to acquiring amyloid PET images increases their value as disease and drug response biomarkers. Most 18 F PET amyloid brain scans often are assessed only visually (per regulatory labels), with a binary decision indicating the presence or absence of Alzheimer disease amyloid pathology. Minimizing technical variance allows precise, quantitative SUV ratios (SUVRs) for early detection of β-amyloid plaques and allows the effectiveness of antiamyloid treatments to be assessed with serial studies. Methods: The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments. Results: On achieving conformance, sites can justify a claim that brain amyloid burden reflected by the SUVR is measurable to a within-subject coefficient of variation of no more than 1.94% when the same radiopharmaceutical, scanner, acquisition, and analysis protocols are used. Conclusion: This overview explains the claim, requirements, barriers, and potential future developments of the profile to achieve precision in clinical and research amyloid PET imaging. (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu